Dana Investment Advisors Inc. Boosts Stake in Boston Scientific Corporation $BSX

Posted by Stanley Muller on May 17th, 2026

Boston Scientific logo Dana Investment Advisors Inc. raised its holdings in Boston Scientific Corporation (NYSE:BSX – Free Report) by 12.8% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 146,537 shares of the medical equipment provider’s stock after purchasing an additional 16,674 shares during the quarter. Dana Investment Advisors Inc.’s holdings in Boston Scientific were worth $13,972,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Murphy & Mullick Capital Management Corp raised its position in Boston Scientific by 200.0% in the third quarter. Murphy & Mullick Capital Management Corp now owns 255 shares of the medical equipment provider’s stock valued at $25,000 after purchasing an additional 170 shares during the period. FWL Investment Management LLC purchased a new stake in Boston Scientific in the second quarter valued at $26,000. United Community Bank raised its position in Boston Scientific by 115.7% in the third quarter. United Community Bank now owns 274 shares of the medical equipment provider’s stock valued at $27,000 after purchasing an additional 147 shares during the period. Colonial Trust Co SC raised its position in Boston Scientific by 502.2% in the third quarter. Colonial Trust Co SC now owns 277 shares of the medical equipment provider’s stock valued at $27,000 after purchasing an additional 231 shares during the period. Finally, Bangor Savings Bank raised its holdings in shares of Boston Scientific by 94.7% in the 4th quarter. Bangor Savings Bank now owns 292 shares of the medical equipment provider’s stock valued at $28,000 after buying an additional 142 shares during the period. Hedge funds and other institutional investors own 89.07% of the company’s stock.

Wall Street Analysts Forecast Growth

BSX has been the topic of several research analyst reports. Citigroup cut their price objective on Boston Scientific from $94.00 to $87.00 and set a “buy” rating on the stock in a report on Tuesday, April 7th. Argus upgraded Boston Scientific to a “strong-buy” rating in a report on Thursday, February 26th. Daiwa Securities Group downgraded Boston Scientific from a “strong-buy” rating to a “hold” rating in a report on Wednesday, April 29th. Needham & Company LLC cut their price objective on Boston Scientific from $97.00 to $77.00 and set a “buy” rating on the stock in a report on Thursday, April 23rd. Finally, UBS Group cut their price objective on Boston Scientific from $120.00 to $105.00 and set a “buy” rating on the stock in a report on Tuesday, March 17th. One analyst has rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $93.91.

Get Our Latest Report on Boston Scientific

Boston Scientific Trading Down 1.7%

BSX opened at $52.67 on Friday. Boston Scientific Corporation has a 12 month low of $52.52 and a 12 month high of $109.50. The stock has a market capitalization of $78.27 billion, a price-to-earnings ratio of 22.04, a PEG ratio of 0.97 and a beta of 0.62. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.90 and a quick ratio of 1.22. The business has a fifty day moving average price of $63.40 and a 200 day moving average price of $81.79.

Boston Scientific (NYSE:BSX – Get Free Report) last released its earnings results on Wednesday, April 22nd. The medical equipment provider reported $0.80 EPS for the quarter, topping the consensus estimate of $0.79 by $0.01. The firm had revenue of $5.20 billion during the quarter, compared to analysts’ expectations of $5.19 billion. Boston Scientific had a return on equity of 19.17% and a net margin of 17.29%.Boston Scientific’s revenue for the quarter was up 11.6% on a year-over-year basis. During the same period in the previous year, the firm posted $0.75 EPS. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. Sell-side analysts expect that Boston Scientific Corporation will post 3.38 earnings per share for the current fiscal year.

Boston Scientific Profile

(Free Report)

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.